F S&P 500
5,356.50 +28.50 (+0.53%) F Dow Jones
39,819.00 +36.00 (+0.09%) F Nasdaq
18,955.50 +168.75 (+0.90%) E-mini Russell 2000 Index Futur
2,094.80 +5.70 (+0.27%) Petróleo
78.27 +0.70 (+0.90%) Oro
2,366.50 -26.40 (-1.10%)
Avivagen Inc. (VIVXF)
Avivagen Inc.
100 Sussex Drive
Ottawa, ON K1A 0R6
Canada
613-702-2908
https://www.avivagen.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. G. F. Kym Anthony | CEO & Vice Chairman | 264.68k | N/D | 1956 |
| Dr. Graham Burton Ph.D. | Co-Founder, Chief Scientific Officer & Director | 92.61k | N/D | N/D |
| Mr. Ira Levy | Interim Chief Financial Officer | 88.24k | N/D | N/D |
| Dr. James Nickerson Ph.D. | President and Executive VP of Business Development & Product Innovation | N/D | N/D | N/D |
| Mr. Drew Basek | Director of Investor Relations | N/D | N/D | N/D |
| Ms. Tracy Gillett BVSC | Director of Companion Animal & Marketing Manager | N/D | N/D | N/D |
Descripción
Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in Canada, Mexico, Brazil, the Philippines, Taiwan, and Thailand. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.
Gestión corporativa
La calificación ISS Governance QuickScore de Avivagen Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
